
The White House has issued an executive order to expedite the review of psychedelic therapies for serious mental illnesses, including those that could potentially benefit individuals with ADHD. This move could pave the way for future research into ADHD-focused treatments.
Executive Order Details
The executive order directs the FDA to prioritize the review of psychedelic therapies, including those using ibogaine, psilocybin, and MDMA, for the treatment of serious mental illnesses. The order also outlines funding and access mechanisms to support this research.
Breaking: White House issues executive order to accelerate review of psychedelic therapies for serious mental illnesses. What does this mean for future #ADHD research?
Potential Impact on ADHD Research
Although ADHD is not specifically mentioned in the executive order, the framework established could accelerate future research into ADHD-focused treatments using psychedelic therapies. A 2025 clinical trial found that low-dose LSD was ineffective for ADHD, highlighting the need for further research into different compounds and dosing strategies.
Quote: “The White House’s executive order marks a significant shift in the approach to mental health research, acknowledging the potential of psychedelic therapies to address serious mental illnesses.” Attribution: Laura Lurns, Education News Reporter and Editor
Laura Lurns · Learning Success expert
Current State of Psychedelic Research
Psychedelic therapies have shown promise in treating various mental health conditions, including depression, anxiety, and PTSD. However, more research is needed to fully understand their potential benefits and risks, particularly in relation to ADHD.
Key takeaways
- Executive Order: Directs FDA to prioritize review of psychedelic therapies for serious mental illnesses.
- Potential ADHD Benefit: Framework could accelerate future ADHD-focused research.
- Current Research: Psychedelic therapies show promise for various mental health conditions, but more research is needed.
Next Steps
The FDA will prioritize the review of psychedelic therapies under the executive order. Researchers and clinicians will need to work together to design and conduct studies that can provide the necessary evidence for the approval of these treatments. Parents and individuals with ADHD should stay informed about the progress of this research and its potential implications.
As research into psychedelic therapies continues to evolve, it’s essential for parents and individuals with ADHD to stay informed about the potential benefits and risks. The Learning Success All Access Program offers a free trial that includes a personalized Action Plan, providing a comprehensive approach to addressing ADHD and other learning differences.
See what All Access gives your childIs your child struggling in school?
Get your free personalized learning roadmap
You describe what you see at home. We turn it into a plan you start this week.
- Answer 5 short questionnaires about what you already notice, 30–45 minutes at your own kitchen table
- Your child sits no test and gets no score: nothing to schedule, nothing for them to dread
- You do the answering, the AI does the writing, and a person reviews it before it reaches you
- Access all 40+ courses instantly: reading, math, focus, processing and more, with new ones added regularly
Why we use AI, plainly: it writes from a knowledge base our team maintains and audits. We work through it line by line and pull anything the evidence stops supporting. The roadmap you get on Tuesday reflects what we corrected on Monday, and a human still reads it before you do.
Your school district must evaluate your child free of charge if you ask in writing, whatever your income and whatever the outcome (US, 34 CFR 300.111 and 300.301(b)). That route takes time and answers a different question than you do. This one starts today, from what you already know.
Your answers stay yours. We do not sell your personal information, and we do not hand identifiable assessment data to outside AI companies to train their models.
A screener is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing or medical cause, pursue a professional evaluation too. That is the only route to those supports.



